One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Axing of Public Health England: disease prevention in limbo
doi : 10.1016/S2468-1253(20)30273-9
Volume 5, Issue 10, October 2020, Page 875
Integrated care for disorders of gut–brain interaction
William DCheya
Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice?
NailaArebia
Global prevalence of irritable bowel syndrome: time to consider factors beyond diagnostic criteria?
Dipesh HVasantab
HCV eradication in chronic kidney disease: ready for prime time?
AnnetteBruchfelda
Improving global digestive health: the gastroenterologists' role
KenechukwuChudy-OnwugajeaErik Cvon Rosenvingeacb
Shifting paradigms in the systemic management of hepatocellular carcinoma
David JPinatoa
Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder
Jin UnKimabAmirMajidbRebekahJudgebPeterCrookbRooshiNathwanibNowlanSelvapattbJamesLovendoskibPinelopiManousouabMarkThurszaAmeetDharabHeatherLewisbNikhilVergisabMaudLemoineab
IBD in the COVID-19 era: the value of international collaboration
Erica JBrenneraRyan CUngarobJean-FredericColombelbMichael DKappelmana
Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial
ChamaraBasnayakeMDabProfMichael AKammMDabAnnaliseStanleyRNaAmyWilson-O'BrienPhDbKathrynBurrellRNaIsabellaLees-TrincaB PhysioaAngelaKheraB PhysioabJimKantidakisPsyDaOliviaWongMDaKateFoxAPDaProfNicholas JTalleyMDdProfDannyLiewMDcMichael RSalzbergMDbProfAlexander JThompsonMDab
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial
Toer WStevensMDa*Maria LHaasnootMDa*ProfGeert RD'HaensPhDaChristianne JBuskensPhDbE Jolinede GroofPhDbEmma JEshuisPhDaTjibbe JGardenbroekPhDbBregjeMolMDaPieter C FStokkersPhDcProfWillem ABemelmanPhDb†ProfCyriel YPonsioenPhDaâ€
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis
PriyaOkaMBBSab*HeatherParrMBBSab*BrigidaBarberioMDc*Christopher JBlackMBBSabProfEdoardo VSavarinoPhDc†ProfAlexander CFordMDabâ€
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
EricLawitzMDaCharles SLandisMDbSteven LFlammMDcMaurizioBonaciniMDdGrisellOrtiz-LasantaMDeJonathanHuangDOfJieZhangPhDgBrian JKirbyPhDgShampaDe-OertelPhDgRobert HHylandDPhilgAnu OOsinusiMDgDiana MBrainardMDgRichardRobsonMBChBhBenedict JMaliakkalMDfStuart CGordonMDiEdward JGaneMDj
Global hepatitis C elimination: an investment framework
AlisaPedranaPhDabJessicaHowellPhDadeNickScottPhDabSophiaSchroederMPHabChristianKuschelPhDaProfJeffrey VLazarusPhDfProfRifatAtunPhDgRicardoBaptista-LeiteMDhiEllen't HoenPhDjkProfSharon JHutchinsonPhDlmLisaAufeggerPhDnRaquelPeckMJoAnnette HSohnMDpTracySwanqProfMarkThurszPhDrProfOlufunmilayoLesiPhDsManikSharmaMDtProfJohnThwaitesPhDu…ProfMargaretHellardPhDabcv
A model of the economic benefits of global hepatitis C elimination: an investment case
NickScottPhDabChristianKuschelPhDaAlisaPedranaPhDabSophiaSchroederMScabJessicaHowellPhDabcdProfAlexanderThompsonPhDcdProfDavid PWilsonPhDab†ProfMargaretHellardPhDabefâ€
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?
AdamPalayewBScaHomieRazaviPhDbProfSharon JHutchinsonPhDcProfGraham SCookeFRCPd†ProfJeffrey VLazarusPhDeâ€
Halo sign and araneid limb-like sign in eosinophilic enteritis
XingHuangMDaXiangqiLiaoMDaZhigangXiaoMDaZhongchengHuangMDa
